Study Details
Real-World Study of ABBV-951 to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
(IRB#: IRB_00178644)
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time and how quickly it progresses varies from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. ABBV-951 is an approved drug for the treatment of PD. This study will see how well ABBV-951 is in treating adult participants with advanced PD in real world setting such as daily living activities, disease progression, and sleep quality. People in the study will receive ABBV-951. Being in the study requires attending regular in person visits at the study clinic for about 3 years. Medical tests and surveys will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 18 years and older
- Eligible to receive the ABBV-951 treatment
- Diagnosis of levodopa-responsive idiopathic Parkinson's disease
- New to or pretreated with ABBV-951
- Able to attend in person visits at the study clinic
Exclusion Criteria
- Current participation in another clinical study
- History of serious skin condition or disorders such as psoriasis, atopic dermatitis
- Mental health condition that impacts full participation
Will I be paid for my time?
Yes
IRB#: IRB_00178644
PI: Paolo Moretti
Department: NEUROLOGY
Approval Date: 2025-05-09 20:42:00
Study Categories: Brain Health Studies
Specialties: Neurology
I am Interested